ライフサイエンスコーパス: hypoglycemic agent

1 ontrol group (48 patients taking alternative hypoglycemic agent).

2 mmol/L or treatment with either insulin or a hypoglycemic agent.

3 y is often superior to therapy with a single hypoglycemic agent.

4 P4 inhibitors) and were noninferior to other hypoglycemic agents.

5 e drugs, but none was using insulin or other hypoglycemic agents.

6 ulfonylurea drugs, the most widely used oral hypoglycemic agents.

7 sions or patients taking any insulin or oral hypoglycemic agents 1 month or later after kidney transp

8 , oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%).

9 required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin).

10 In order to identify such hypoglycemic agents, a novel assay for activators of glu

11 n of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialysis p

12 xercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of incr

13 etes was ascertained by using information on hypoglycemic agents and serum glucose.

14 obtained from patients taking long-term oral hypoglycemic agents and were also exposed to 5 minutes o

15 ns: the first (control) while receiving oral hypoglycemic agents, and the second after the addition o

16 m, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2

17 The newer oral hypoglycemic agents are also in use and have mechanisms

18 Oral hypoglycemic agents are inhibitors of the ATP-sensitive

19 has been prepared which contains many potent hypoglycemic agents as demonstrated by assessing glucose

20 insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured b

21 filled a prescription for insulin or an oral hypoglycemic agent during the 120 days before admission,

22 Patients receiving oral hypoglycemic agents for diabetes mellitus are at increas

23 an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 d

24 t amelioration of hyperglycemia by different hypoglycemic agents forestalled PI-producing ATM accumul

25 Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylureas) i

26 Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class.

27 alpha-amylase, a therapeutic target for oral hypoglycemic agents in type-2 diabetes.

28 patients without long-term exposure to oral hypoglycemic agents is functionally protected by precond

29 onic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher New Yor

30 g-term inhibition of KATP channels with oral hypoglycemic agents may explain the excess cardiovascula

31 r, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione, sulfo

32 tory of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and lower New Y

33 litazone maleate is the second approved oral hypoglycemic agent of the thiazolidinedione class.

34 s with type 2 diabetes---7 treated with oral hypoglycemic agents (OHA R(X); mean [+/- SD] HbA(1c) 8.6

35 ose not fasting), the use of insulin or oral hypoglycemic agents, or self-reported history.

36 In patients receiving long-term oral hypoglycemic agents (Oral Hypo+IPC), recovery of DF was

37 Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitazone h

38 oglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug

39 Troglitazone is an orally active hypoglycemic agent that has been shown to ameliorate ins

40 Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate ins

41 h 30-year-old studies on the pharmacology of hypoglycemic agents, the pocket is bipartite.

42 >/= 7.0 mmol/L) >/= 30 days apart, (ii) oral hypoglycemic agent use for >/= 30 consecutive days, (iii

43 load glucose >/=200 mg/dL, HbA1c >/=6.5%, or hypoglycemic agent use.

44 Only the associations with systemic hypoglycemic agents were greater than 1 mm Hg, a thresho

45 vels, lived in Eastern Europe or were taking hypoglycemic agents, were more likely to have impaired Q

46 ogues, antihypertensive agents, statins, and hypoglycemic agents, whereas in spite of the prominent r

47 SAH 51-641 (1) is a potent hypoglycemic agent, which acts by inhibiting hepatic glu

48 ither taking no medication or taking an oral hypoglycemic agent (with or without insulin) were classi

49 ocardium from patients taking long-term oral hypoglycemic agents would be resistant to the protection